CD274 and non-small cell lung carcinoma: Programmed death 1/programmed death ligand 1 (PD-1/PD-L1) inhibitors (immune checkpoints inhibitors, ICI), have been approved worldwide as therapeutic agents for immunotherapy in advanced non-small cell lung cancer (NSCLC) [1,2,3,4].